Bronte Capital Management Pty Ltd. Sells 10,977 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Bronte Capital Management Pty Ltd. cut its position in iShares Biotechnology ETF (NASDAQ:IBB) by 3.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 272,443 shares of the financial services provider’s stock after selling 10,977 shares during the quarter. iShares Biotechnology ETF comprises about 3.1% of Bronte Capital Management Pty Ltd.’s portfolio, making the stock its 12th biggest holding. Bronte Capital Management Pty Ltd. owned approximately 0.51% of iShares Biotechnology ETF worth $37,396,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Blue Fin Capital Inc. increased its holdings in shares of iShares Biotechnology ETF by 0.7% during the second quarter. Blue Fin Capital Inc. now owns 10,516 shares of the financial services provider’s stock worth $1,443,000 after purchasing an additional 74 shares during the period. Crewe Advisors LLC grew its holdings in shares of iShares Biotechnology ETF by 42.9% during the 4th quarter. Crewe Advisors LLC now owns 260 shares of the financial services provider’s stock worth $35,000 after purchasing an additional 78 shares in the last quarter. Apexium Financial LP increased its position in shares of iShares Biotechnology ETF by 3.8% in the fourth quarter. Apexium Financial LP now owns 2,223 shares of the financial services provider’s stock worth $302,000 after purchasing an additional 82 shares during the period. Perkins Coie Trust Co raised its stake in iShares Biotechnology ETF by 0.3% in the second quarter. Perkins Coie Trust Co now owns 25,184 shares of the financial services provider’s stock valued at $3,457,000 after purchasing an additional 83 shares in the last quarter. Finally, HCR Wealth Advisors lifted its position in iShares Biotechnology ETF by 0.6% during the second quarter. HCR Wealth Advisors now owns 13,453 shares of the financial services provider’s stock worth $1,847,000 after purchasing an additional 83 shares during the period. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Trading Up 1.2 %

Shares of iShares Biotechnology ETF stock opened at $144.53 on Tuesday. The firm’s 50-day moving average price is $144.27 and its two-hundred day moving average price is $138.08. iShares Biotechnology ETF has a 12-month low of $111.83 and a 12-month high of $150.17.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.